

National Institutes of Health National Institute of Mental Health 6001 Executive Boulevard Bethesda, Maryland 20892

DATE: November 9, 2021

TO:Office of Management and Budget (OMB)Through:Reports Clearance Officer, Terry Clark, DHHS1Project Clearance Chief, Mikia Currie, NIH

- FROM: Mikia Currie, Project Clearance Branch (PCB)
- SUBJECT: Federal COVID Response Audience Feedback to Inform Ongoing Messaging and Strategies for "Combat COVID"#0925-0769, Expiration Date 12/31/2021)

This is a request for OMB to approve non-substantive changes to the Federal COVID Response - Audience Feedback to Inform Ongoing Messaging and Strategies for "Combat COVID" custom web survey data collection instrument approved under OMB Control #0925-0769, Expiration Date: 12/31/2021.

The Custom Web Survey with Consumer and Provider Paths collects information on target audience members knowledge of COVID-19 treatments, awareness of Combat COVID over time, and reported outcomes after interacting with Combat COVID messages (such as visiting website or sharing information with patients).

We are requesting approval of minor changes to the questions on recall of Combat COVID materials and knowledge of/experience with new COVID-19 treatments. The changes to the web survey will not meaningfully alter the content, scope, or method of the information collection. The changes to the survey are described below.

<u>Updates to the survey:</u>

- Replacements/Additions:
 - o Audio/visual test (for playing message stimuli)
 - 0 Knowledge of monoclonal antibodies and antivirals
 - o Trust in COVID-19 treatments, monoclonal antibodies, and antivirals for COVID-19
 - 0 Likelihood of enrolling in an at-home clinical trial
 - 0 Likelihood of seeking out monoclonal antibodies if sick with COVID-19
 - o Updated Combat COVID recall stimuli
 - Revised COVID-19 experience question to ask about confirmation testing and whether respondent sought monoclonal antibodies for treatment
 - **o** Revised COVID-19 concern question as a scalar question (not binary choice)
 - o Provider discussions of monoclonal antibodies and COVID-19 boosters with patients

- Deletions:
 - o Awareness of clinical trial names
 - Open response question for rating trust in clinical trials
 - 0 Rating of trust in clinical trials for COVID-19 funded by the federal government
 - o Open response for providers' likelihood of referring a patient to a clinical trial
 - 0 Open response on purpose of Combat COVID website
 - Message affect question (e.g., "the Combat COVID messages is for someone like me")
 - 0 Removed COVID-19 caregiver experience question
 - o Removed COVID-19 hospitalization question
 - o Removed COVID-19 fear question

This update does not affect the burden.

Your full consideration is appreciated.

Attachments:

- A. Revised tracked changes copy of the Custom Web Survey with Consumer and Provider Paths
- B. Revised clean copy of the Custom Web Survey with Consumer and Provider Paths